JP4658809B2 - Gfpおよびその他の蛍光タンパク質トランスジェニックヌードマウス - Google Patents
Gfpおよびその他の蛍光タンパク質トランスジェニックヌードマウス Download PDFInfo
- Publication number
- JP4658809B2 JP4658809B2 JP2005518144A JP2005518144A JP4658809B2 JP 4658809 B2 JP4658809 B2 JP 4658809B2 JP 2005518144 A JP2005518144 A JP 2005518144A JP 2005518144 A JP2005518144 A JP 2005518144A JP 4658809 B2 JP4658809 B2 JP 4658809B2
- Authority
- JP
- Japan
- Prior art keywords
- mouse
- gfp
- fluorescent protein
- mice
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000034287 fluorescent proteins Human genes 0.000 title claims description 18
- 108091006047 fluorescent proteins Proteins 0.000 title claims description 18
- 238000011580 nude mouse model Methods 0.000 title description 16
- 241000699660 Mus musculus Species 0.000 title description 15
- 230000009261 transgenic effect Effects 0.000 title description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 24
- 238000003384 imaging method Methods 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000011830 transgenic mouse model Methods 0.000 claims description 7
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000004020 luminiscence type Methods 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 2
- 230000008614 cellular interaction Effects 0.000 claims 1
- 238000000295 emission spectrum Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 description 60
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 57
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000005747 tumor angiogenesis Effects 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 238000012634 optical imaging Methods 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000242583 Scyphozoa Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 description 1
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
と移植された細胞もしくは組織との間の相互作用に対するさまざまな薬剤の効果をスクリーニングするのに使用することもできる。こうした薬剤の例としては、宿主-移植片相互作用を調節する、または移植された細胞もしくは組織の増殖および広がりを調節する、薬物もしくは候補薬物がある。
そこで一代雑種(F1)を集め、相互に交配させてGFP発現nu/nuマウスを含めた子孫を生み出す。その後F1×F1交配から得られた雄および雌のGFP発現nu/nuマウスを用いて、GFP発現nu/nuマウス子孫を作り出す。これらの結果として得られたマウスをnu/nu GFP非発現nu/nuマウスと交配してGFP発現nu/nuマウスを維持することができる。
C-57 B16-GFPマウスをnu/nuマウスと交配した。
F1世代を集めて相互に交配した。2匹のまれなGFP nu/nuマウス、1匹の雄と1匹の雌が得られた。このGFP nu/nu雄およびGFP nu/nu雌を互いに交配して、同腹の6匹のGFP nu/nuマウスを作製した。
雄のGFP nu/nuマウスを雌のnu/nu非GFPマウスと交配した。9匹のヌードnu/nu出生仔が生まれた。すべてが全体的に蛍光を発現した。
Claims (5)
- 薬物の腫瘍-宿主相互作用への影響をアッセイする方法であって、
免疫無防備状態のトランスジェニックマウスを前記薬物と接触させる工程、ここで、前記マウスは、第1の蛍光タンパク質に適合した励起照射にさらした時に前記蛍光タンパク質によって放出される光の色が完全に現れるように基本的にすべての組織において前記蛍光タンパク質を発現するが、マウスの免疫無防備状態の表現型は維持しており、前記マウスには腫瘍細胞が移植されており、また前記腫瘍細胞は、第1の蛍光タンパク質とは異なる発光スペクトルを有する第2の蛍光タンパク質を発現するよう改変されている、;
前記第1および第2の蛍光タンパク質の発光を観察することによって、腫瘍−宿主細胞相互作用を画像化する工程;および
結果として得られた画像を前記薬物と接触させなかった対照マウスとを比較する工程;
を含んでなる、前記方法。 - 前記観察が生きている無傷のマウスの全身イメージングによる、請求項1に記載の方法。
- 前記腫瘍細胞が前記マウスに同所移植される、請求項1または2に記載の方法。
- 第1の蛍光タンパク質が緑色であり、第2の蛍光タンパク質が赤色である請求項1−3のいずれか1つに記載の方法。
- 免疫無防備状態のマウスがnu/nuマウスである請求項1−4のいずれか1つに記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44558303P | 2003-02-07 | 2003-02-07 | |
PCT/US2004/003636 WO2004072098A2 (en) | 2003-02-07 | 2004-02-09 | Immunocompromised rodents as dual color tumor models |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006514830A JP2006514830A (ja) | 2006-05-18 |
JP4658809B2 true JP4658809B2 (ja) | 2011-03-23 |
Family
ID=32869384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005518144A Expired - Fee Related JP4658809B2 (ja) | 2003-02-07 | 2004-02-09 | Gfpおよびその他の蛍光タンパク質トランスジェニックヌードマウス |
Country Status (9)
Country | Link |
---|---|
US (1) | US8148600B2 (ja) |
EP (1) | EP1590663B1 (ja) |
JP (1) | JP4658809B2 (ja) |
KR (1) | KR101142610B1 (ja) |
CN (1) | CN1947006B (ja) |
AU (1) | AU2004212465B2 (ja) |
CA (1) | CA2515203C (ja) |
DE (1) | DE602004031081D1 (ja) |
WO (1) | WO2004072098A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8679836B2 (en) * | 2007-10-01 | 2014-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures |
US20090088341A1 (en) * | 2007-10-01 | 2009-04-02 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Multiplex assay method for mixed cell populations |
WO2010096044A1 (en) * | 2008-10-30 | 2010-08-26 | Albert Einstein College Of Medicine Of Yeshiva University | In vivo quantitative screening test for anti-metastasis treatment efficacy |
CN110547249A (zh) * | 2019-09-11 | 2019-12-10 | 苏州大学 | 一种升主动脉瘤动物模型的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251384B1 (en) * | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
AU2002211460A1 (en) * | 2000-10-06 | 2002-04-15 | Johns Hopkins University School Of Medicine | Derivation of human tumor cell lines using passage in transgenic mice having selectable markers |
US20020120946A1 (en) | 2000-12-22 | 2002-08-29 | Michael Breindl | Transgenic constructs for studying fibrotic diseases and uses thereof |
-
2004
- 2004-02-09 CA CA2515203A patent/CA2515203C/en not_active Expired - Fee Related
- 2004-02-09 EP EP04709430A patent/EP1590663B1/en not_active Expired - Lifetime
- 2004-02-09 KR KR1020057014592A patent/KR101142610B1/ko active IP Right Grant
- 2004-02-09 AU AU2004212465A patent/AU2004212465B2/en not_active Ceased
- 2004-02-09 US US10/775,554 patent/US8148600B2/en not_active Expired - Fee Related
- 2004-02-09 JP JP2005518144A patent/JP4658809B2/ja not_active Expired - Fee Related
- 2004-02-09 DE DE602004031081T patent/DE602004031081D1/de not_active Expired - Lifetime
- 2004-02-09 WO PCT/US2004/003636 patent/WO2004072098A2/en active Application Filing
- 2004-02-09 CN CN200480009199.9A patent/CN1947006B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8148600B2 (en) | 2012-04-03 |
CN1947006A (zh) | 2007-04-11 |
EP1590663B1 (en) | 2011-01-19 |
US20040231013A1 (en) | 2004-11-18 |
KR20050095646A (ko) | 2005-09-29 |
AU2004212465A1 (en) | 2004-08-26 |
CA2515203C (en) | 2015-11-24 |
AU2004212465B2 (en) | 2009-09-10 |
WO2004072098A3 (en) | 2005-03-17 |
KR101142610B1 (ko) | 2012-05-10 |
WO2004072098A2 (en) | 2004-08-26 |
EP1590663A2 (en) | 2005-11-02 |
CN1947006B (zh) | 2014-11-05 |
JP2006514830A (ja) | 2006-05-18 |
DE602004031081D1 (de) | 2011-03-03 |
CA2515203A1 (en) | 2004-08-26 |
EP1590663A4 (en) | 2006-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muzumdar et al. | A global double‐fluorescent Cre reporter mouse | |
JP3709343B2 (ja) | マーカーとして緑色蛍光タンパク質(gfp)を使用する転移モデル | |
JP5342397B2 (ja) | 腫瘍転移の解像度の向上 | |
JP2001517090A (ja) | マーカーとして緑色蛍光タンパク質(gfp)を利用するがん転移モデル | |
US20080038204A1 (en) | Whole Body Imaging Using Portable Observation Systems | |
Bouvet et al. | Tumor imaging technologies in mouse models | |
JP4658809B2 (ja) | Gfpおよびその他の蛍光タンパク質トランスジェニックヌードマウス | |
US20020178460A1 (en) | Transgenic mice expressing fluorescent protein | |
AU2002326872A1 (en) | Enhanced resolution of tumor metastasis | |
van der Horst et al. | Preclinical models that illuminate the bone metastasis cascade | |
Sakamaki et al. | Transgenic frogs expressing the highly fluorescent protein venus under the control of a strong mammalian promoter suitable for monitoring living cells | |
Adams et al. | High resolution gene expression analysis in mice using genetically inserted reporter genes | |
Hoffman | Whole-body fluorescence imaging with green fluorescence protein | |
Tilli et al. | Comparison of mouse mammary gland imaging techniques and applications: reflectance confocal microscopy, GFP imaging, and ultrasound | |
Hoffman | Nestin-driven green fluorescent protein as an imaging marker for nascent blood vessels in mouse models of cancer | |
WO2013102118A2 (en) | Imageable patient tumors in mice | |
Katz | SILVER LININGS: APPLICATIONS OF SILVER STAINING FOR | |
Hoffman | Subcellular imaging of cancer cells in live mice | |
Hoffman | AngioMouse: imageable models of angiogenesis | |
Bouvet et al. | Preclinical fluorescent mouse models of pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060718 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070215 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070330 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100623 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101109 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140107 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4658809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140107 Year of fee payment: 3 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |